gh C级）受试者中使用奈玛特韦或利托那韦的药代动力学或安全性数据，因此Paxlovid在严重肝损伤患者中禁用。
利托那韦或含钴司他方案的联合治疗
无需调整剂量；Paxlovid的剂量为300mg/100mg，每天两次，持续5天。
被诊断为人类免疫缺陷病毒（HIV）或丙型肝炎病毒（HCV）感染的患者，如果正在接受含有利托那韦或钴酸盐的治疗方案，则应按照指示继续治疗。
禁忌症
Paxlovid患者禁用：
-对所列的活性物质（奈玛特韦/利托那韦）或任何赋形剂有临床显著过敏史。
-严重肝损害。
-严重肾损害。
Paxlovid也禁用于高度依赖CYP3A清除的药物，并且血浆浓度升高与严重和/或危及生命的反应相关。Paxlovid也禁用于作为CYP3A诱导剂的药物产品，其中血浆奈玛特韦/利托那韦浓度显著降低可能与病毒应答丧失和可能的耐药性相关。
禁止与尼松韦/利托那韦同时使用的药物[见原说明资料]
保质期
2年。
储存的特殊预防措施
储存温度低于25°C。
不要冷藏或冷冻。
容器的性质和内容
Paxlovid包装在纸箱中，纸箱中包含5个每日剂量的OPA/Al/PVC箔泡罩卡，30片。
每个每日泡罩卡包含4片奈玛特韦片和2片利托那韦片。
提示：本品仅供专业人员参考！
请参阅随附的Paxlovid完整处方信息：
https://www.medicines.org.uk/emc/product/13145/smpc
----------------------------------------
173 Recovered From Covid-19 After Paxlovid Treatment
The Covid-19 pill is prioritised for Covid-19 patients with mild to moderate symptoms who do not need oxygen support, but have underlying disease like diabetes, hypertension, kidney problems, asthma or chronic lung conditions, heart disease, and cancer.
This product should be considered first for patients with COVID-19 who are 18 years old or older (with COVID-19 infection of category II or III, these patients do not need oxygen treatment, but have potential diseases, such as diabetes, hypertension, kidney problems, asthma or chronic lung disease, heart disease and cancer) to use paclovir.
Eligible COVID-19 patients can go to COVID-19 Assessment Center (CAC) or public hospitals for assessment before taking paclovir. COVID-19 pills can be purchased in 512 CACs and 78 public hospitals nationwide.
The drug should be taken immediately within five days after symptoms appear to obtain the best effect and reduce the risk of more serious complications of COVID-19. ". |
